Table 1.
Baseline characteristics of the intention-to-treat population.
| Characteristics No. (%) |
mCAP-Rabeprazole (n = 32) |
mCAP (n = 35) |
p | |
|---|---|---|---|---|
| Age—years | ||||
| Median (range) | 69 (39–85) | 69 (38–87) | 0.358 | |
| Sex | ||||
| Male | 22 (69) | 20 (57) | 0.449 | |
| Female | 10 (31) | 15 (43) | ||
| ECOG PS | ||||
| 0 | 14 (44) | 9 (26) | 0.197 | |
| 1 | 10 (31) | 18 (51) | ||
| 2 | 8 (25) | 8 (23) | ||
| Primary tumor site | ||||
| Colon or rectum | 28 (87) | 28 (80) | 0.134 | |
| Stomach | 0 (0) | 4 (11) | ||
| Pancreas | 4 (13) | 3 (9) | ||
| Site of metastasis | ||||
| Liver | 16 (50) | 15 (43) | 0.561 | |
| Multiorgan | 8 (25) | 13 (37) | ||
| Peritoneum | 8 (25) | 7 (20) | ||
| n. of prior regimens | ||||
| 1 | 6 (19) | 5 (14) | 0.349 | |
| 2 | 16 (50) | 15 (43) | ||
| ≥3 | 10 (31) | 15 (43) | ||
| Prior anticancer therapy | ||||
| Fluoropyrimidine-based | 14 (44) | 16 (46) | 0.244 | |
| Anti-VEGF | 16 (50) | 10 (28) | ||
| Anti-EGFR | 4 (12) | 6 (17) | ||